source
- Pfizer reports positive Phase 3 results for Elrexfio in relapsed multiple myelomaPfizer announced that its antibody-drug conjugate Elrexfio achieved a statistically significant and clinically meaningful improvement in progression-free survival for patients with relapsed or refr…
- GSK CEO warns possible team reorganization if upcoming Phase 3 readouts fall shortGSK's chief executive Luke Miels told analysts during the first‑quarter earnings call that the company has several pivotal Phase 3 trials slated for this year. He said that if those late‑stage rea…